Advertisement
AORT vs LMAT
Which Stock Would AI Choose? Artivion (AORT) vs. LeMaitre Vascular (LMAT) Stock Comparison
1) Key Takeaways
- AORT is a higher-growth but lower-margin cardiac and aortic device maker pivoting on new FDA approvals, while LMAT is a consistently profitable, cash-rich niche vascular device business.
- Artivion's relative performance has been shaped by regulatory catalysts (AMDS and NEXUS) and acquisition spending, whereas LeMaitre Vascular has been pressured by foreign exchange, Middle East export delays, and a leadership transition.
- LeMaitre Vascular's gross margins near 72% and record operating income contrast with Artivion's thinner profitability and recent swing to a quarterly net loss.
- Both stocks compete for investor capital in medical technology, but they offer very different risk profiles: pipeline-driven growth versus steady, cash-generative profitability.
- Recent market activity shows LeMaitre Vascular shares pulling back sharply while Artivion has drawn bullish analyst initiations tied to upcoming U.S. product launches.
2) Introduction
Medical device investors weighing growth against stability often find themselves comparing two distinct profiles within the cardiovascular space. Artivion, Inc. (AORT) is an Atlanta-based developer of aortic repair technologies and mechanical heart valves, while LeMaitre Vascular, Inc. (LMAT) is a Burlington, Massachusetts-based maker of vascular grafts, shunts, patches, and related biologics. This stock comparison examines their recent market positioning, growth drivers, and risk factors, offering traders and long-term investors a factual framework for evaluating relative performance. The contrast between Artivion's catalyst-heavy pipeline and LeMaitre's disciplined, profitable niche strategy makes this pairing particularly useful for those balancing momentum with fundamental quality.
2) AORT Overview and Recent Performance
Artivion, formerly CryoLife until its 2022 rebrand, develops and markets products across four groups: aortic stent grafts, surgical sealants such as BioGlue, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. The company sells in more than 100 countries and is focused on building what management describes as a complete aortic arch portfolio.
In recent weeks, sentiment around AORT has been shaped by a pair of regulatory and strategic milestones: the U.S. Food and Drug Administration (FDA) premarket approval (PMA) of its AMDS Hybrid Prosthesis and the completed acquisition of Endospan, which adds the NEXUS aortic arch stent graft platform. In its most recent quarters, Artivion reported double-digit constant-currency revenue growth but also lowered full-year guidance and, in the second quarter, swung to a net loss of roughly $13.5 million as acquisition-related costs and higher research spending weighed on results. Management has reaffirmed a full-year revenue outlook centered near $488 million and is targeting a broader U.S. launch of NEXUS in early 2027. Jefferies initiated coverage with a Buy rating in recent trading, citing an "attractive entry point" ahead of these commercial catalysts.
2) LMAT Overview and Recent Performance
LeMaitre Vascular develops, manufactures, and sells devices and biological tissues used in vascular and cardiac surgery worldwide. Its portfolio spans grafts, carotid shunts, patches, catheters, and the Artegraft bovine graft line, which has become its largest and fastest-growing product category.
In recent quarters, LMAT delivered roughly 10% organic sales growth, a gross margin of about 72%, record operating income, and higher net income and earnings per share (EPS). The company also announced a quarterly dividend of $0.25 per share and held roughly $376 million in cash and marketable securities. However, its relative performance has been tempered by headwinds: foreign exchange (FX) pressure from a stronger U.S. dollar, export disruptions tied to conflict in the Middle East, and limited cardiac allograft supply. The stock has pulled back notably over the past several months, and the company recently disclosed that its President plans to retire at year-end, adding a leadership-transition variable to the outlook. Full-year 2026 sales guidance sits in the range of approximately $274 million to $278 million.
5) Trending AI Robots
For traders seeking a data-driven edge across names like AORT and LMAT, Tickeron's Trending AI Robots page curates a focused selection of algorithmic trading systems. Tickeron hosts hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only those best suited to current market conditions earn a place in this curated section. These bots differ widely in trading style, strategy, timeframe, performance statistics, and the sets of tickers they monitor, with many designed to capture short-term momentum while others target longer trend-following opportunities. Reviewing the Trending AI Robots page can help investors observe how automated strategies are positioning across sectors and market regimes.
6) Head-to-Head Comparison
The two companies occupy adjacent but distinct niches in medical technology. Artivion's business model is built around complex, high-value aortic solutions and mechanical valves, where regulatory approvals and new-product adoption drive growth. This creates a catalyst-rich but capital-intensive profile, reflected in thinner margins and a recent quarterly loss tied to the Endospan acquisition. In contrast, LeMaitre Vascular operates a diversified portfolio of niche vascular devices, supported by pricing power, a disciplined acquisition strategy, and strong free cash flow.
On recent momentum, Artivion has benefited from FDA approvals and bullish analyst initiations, while LeMaitre has faced sentiment pressure from guidance-related concerns, FX and export friction, and executive succession. Risk profiles differ accordingly: Artivion carries execution and adoption risk around AMDS and NEXUS, whereas LeMaitre carries concentration risk in a narrower product set alongside regulatory and supply-chain sensitivities. From a sector-exposure standpoint, both serve aging demographics and recurring surgical demand, but Artivion skews toward growth and pipeline optionality while LeMaitre skews toward profitability and balance-sheet strength.
7) Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor AORT in the current environment, while acknowledging the greater uncertainty embedded in that choice. Artivion's combination of fresh regulatory approvals, an expanded aortic arch platform, reaffirmed revenue guidance, and positive analyst catalysts presents a more clearly defined near-term trend and catalyst stack than LeMaitre's current setup, which is contending with a leadership transition, softer sentiment, and a meaningful share-price pullback. That said, the AI's preference would be probabilistic rather than definitive: LeMaitre's superior margins, cash position, and consistent profitability give it greater stability, meaning a momentum-oriented model might favor Artivion while a quality or low-volatility model might favor LeMaitre. Positioning depends heavily on the specific timeframe and strategy of the automated system in question.
8) Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AORT is a Hold and LMAT is a Hold.
AORT's RSI Indicator recovers from oversold territory
The RSI Oscillator for AORT moved out of oversold territory on October 12, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 20 similar instances when the indicator left oversold territory. In 18 of the 20 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on AORT as a result. In 62 of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for AORT just turned positive on October 14, 2026. Looking at past instances where AORT's MACD turned positive, the stock continued to rise in 37 of 47 cases over the following month. The odds of a continued upward trend are 79%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where AORT advanced for three days, in 220 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 44 of 62 cases where AORT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AORT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 67%.
AORT broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for AORT entered a downward trend on October 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 4 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.594) is normal, around the industry mean (4.170). AORT's P/E Ratio (-474.200) is considerably lower than the industry average of (1.500). Projected Growth (PEG Ratio) (4.200) is also within normal values, averaging (11.253). Dividend Yield (0.005) settles around the average of (0.010) among similar stocks. P/S Ratio (2.603) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating fairly steady price growth. AORT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 91 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 95 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AORT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Momentum Indicator for LMAT turns negative, indicating new downward trend
LMAT saw its Momentum Indicator move below the 0 level on November 02, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 104 similar instances where the indicator turned negative. In 62 of the 104 cases, the stock moved further down in the following days. The odds of a decline are at 60%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for LMAT turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 27 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 54%.
LMAT moved below its 50-day moving average on November 03, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LMAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
The 10-day moving average for LMAT crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 12 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
Following a +2.31% 3-day Advance, the price is estimated to grow further. Considering data from situations where LMAT advanced for three days, in 229 of 339 cases, the price rose further within the following month. The odds of a continued upward trend are 68%.
The Aroon Indicator entered an Uptrend today. In 176 of 235 cases where LMAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is 52 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating fairly steady price growth. LMAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 71 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.783) is normal, around the industry mean (4.946). P/E Ratio (30.528) is within average values for comparable stocks, (38.797). Projected Growth (PEG Ratio) (2.178) is also within normal values, averaging (4.143). Dividend Yield (0.011) settles around the average of (0.005) among similar stocks. P/S Ratio (7.267) is also within normal values, averaging (56.876).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
AORT | LMAT | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 82 | 88 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 4 Undervalued | 71 Overvalued | |
PROFIT vs RISK RATING 1..100 | 95 | 54 | |
SMR RATING 1..100 | 91 | 52 | |
PRICE GROWTH RATING 1..100 | 62 | 61 | |
P/E GROWTH RATING 1..100 | 99 | 82 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AORT's Valuation (4) in the Medical Specialties industry is significantly better than the same rating for LMAT (71). This means that AORT’s stock grew significantly faster than LMAT’s over the last 12 months.
LMAT's Profit vs Risk Rating (54) in the Medical Specialties industry is somewhat better than the same rating for AORT (95). This means that LMAT’s stock grew somewhat faster than AORT’s over the last 12 months.
LMAT's SMR Rating (52) in the Medical Specialties industry is somewhat better than the same rating for AORT (91). This means that LMAT’s stock grew somewhat faster than AORT’s over the last 12 months.
LMAT's Price Growth Rating (61) in the Medical Specialties industry is in the same range as AORT (62). This means that LMAT’s stock grew similarly to AORT’s over the last 12 months.
LMAT's P/E Growth Rating (82) in the Medical Specialties industry is in the same range as AORT (99). This means that LMAT’s stock grew similarly to AORT’s over the last 12 months.
| AORT | LMAT | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 71% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 76% | 2 days ago 60% |
| MACD ODDS (%) | 2 days ago 79% | 2 days ago 54% |
| TrendWeek ODDS (%) | 2 days ago 75% | 2 days ago 56% |
| TrendMonth ODDS (%) | 2 days ago 75% | 2 days ago 68% |
| Advances ODDS (%) | 2 days ago 73% | 14 days ago 68% |
| Declines ODDS (%) | 8 days ago 67% | 8 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 80% | N/A |
| Aroon ODDS (%) | 2 days ago 73% | 2 days ago 75% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AORT’s FA Score shows that 1 FA rating(s) are green while LMAT’s FA Score has 0 green FA rating(s).
- AORT’s FA Score: 1 green, 4 red.
- LMAT’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AORT’s TA Score shows that 4 TA indicator(s) are bullish while LMAT’s TA Score has 4 bullish TA indicator(s).
- AORT’s TA Score: 4 bullish, 4 bearish.
- LMAT’s TA Score: 4 bullish, 4 bearish.
Price Growth
AORT (@Medical/Nursing Services) experienced а +3.36% price change this week, while LMAT (@Pharmaceuticals: Other) price change was -3.81% for the same time period.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was +2.37%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was -1.02%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +3.45%. For the same industry, the average monthly price growth was +1.98%, and the average quarterly price growth was +15.93%.
Reported Earning Dates
AORT is expected to report earnings on Nov 05, 2026.
LMAT is expected to report earnings on Nov 04, 2026.
Industries' Descriptions
@Medical/Nursing Services (+2.37% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Pharmaceuticals: Other (+3.45% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
Advertisement
AORT and
Correlation & Price change
A.I.dvisor indicates that over the last year, AORT has been loosely correlated with VREX. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if AORT jumps, then VREX could also see price increases.
| Ticker / NAME | Correlation To AORT | 1D Price Change % | ||
|---|---|---|---|---|
| AORT | 100% | +0.55% | ||
| VREX - AORT | 55% Loosely correlated | +0.38% | ||
| TCMD - AORT | 43% Loosely correlated | +8.35% | ||
| LMAT - AORT | 42% Loosely correlated | -0.81% | ||
| ISRG - AORT | 39% Loosely correlated | +0.89% | ||
| UTMD - AORT | 39% Loosely correlated | -0.75% | ||
More | ||||
LMAT and
Correlation & Price change
A.I.dvisor indicates that over the last year, LMAT has been loosely correlated with ITGR. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if LMAT jumps, then ITGR could also see price increases.
| Ticker / NAME | Correlation To LMAT | 1D Price Change % | ||
|---|---|---|---|---|
| LMAT | 100% | -0.81% | ||
| ITGR - LMAT | 48% Loosely correlated | N/A | ||
| SYK - LMAT | 46% Loosely correlated | +1.22% | ||
| UFPT - LMAT | 44% Loosely correlated | -1.29% | ||
| AORT - LMAT | 40% Loosely correlated | +0.55% | ||
| RDNT - LMAT | 39% Loosely correlated | +0.11% | ||
More | ||||